Table 4.
COVID-19 Vaccines General Side Effects of Participating German Healthcare Workers, February–March 2021 (n = 599).
| Variable | Outcome | mRNA Vaccine | Viral Vector Vaccine | Total | Sig. |
|---|---|---|---|---|---|
| Local SE | Injection Site Pain | 367 (77.4%) | 86 (68.8%) | 453 (75.6%) | 0.046 |
| Injection Site Swelling | 88 (18.6%) | 20 (16%) | 108 (18%) | 0.507 | |
| Injection Site Redness | 51 (10.8%) | 11 (8.8%) | 62 (10.4%) | 0.522 | |
| Intensity (μ ± SD) | 1.07 ± 0.80 | 0.94 ± 0.81 | 1.04 ± 0.81 | 0.069 | |
| Total | 371 (78.3%) | 88 (70.4%) | 459 (76.6%) | 0.064 | |
| Systemic SE | Fever | 47 (9.9%) | 60 (48%) | 107 (17.9%) | <0.001 |
| Chills | 66 (13.9%) | 72 (57.6%) | 138 (23%) | <0.001 | |
| Headache/Fatigue | 228 (48.1%) | 93 (74.4%) | 321 (53.6%) | <0.001 | |
| Muscle Pain | 133 (28.1%) | 66 (52.8%) | 199 (33.2%) | <0.001 | |
| Joint Pain | 68 (14.3%) | 59 (47.2%) | 127 (21.2%) | <0.001 | |
| Nausea | 39 (8.2%) | 26 (20.8%) | 65 (10.9%) | <0.001 | |
| Malaise | 89 (18.8%) | 61 (48.8%) | 150 (25%) | <0.001 | |
| Lymphadenopathy | 43 (9.1%) | 13 (10.4%) | 56 (9.3%) | 0.650 | |
| Intensity (μ ± SD) | 1.50 ± 1.75 | 3.60 ± 2.25 | 1.94 ± 2.05 | <0.001 | |
| Total | 289 (61%) | 109 (87.2%) | 398 (66.4%) | <0.001 | |
| General SE Duration | 1 Day | 161 (39.6%) | 51 (44.3%) | 212 (40.6%) | 0.155 |
| 3 Days | 190 (46.7%) | 41 (35.7%) | 231 (44.3%) | 0.137 | |
| 5 Days | 22 (5.4%) | 6 (5.2%) | 28 (5.4%) | 0.940 | |
| 1 Week | 21 (5.2%) | 5 (4.3%) | 26 (5%) | 0.834 | |
| >1 Week | 12 (2.9%) | 12 (10.4%) | 24 (4.6%) | 0.001 | |
| >1 Month | 1 (0.2%) | 0 (0%) | 1 (0.2%) | 1.000 * | |
| General SE | Intensity (μ ± SD) | 2.57 ± 2.16 | 4.54 ± 2.75 | 2.98 ± 2.43 | <0.001 |
| Total | 413 (87.1%) | 115 (92%) | 528 (88.1%) | 0.134 | |
| Severe SE | Total | 2 (0.4%) | 4 (3.2%) | 6 (1%) | 0.019 * |
Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.